UC Berkeley’s cell therapy developer has filed for an initial public offering.
Caribou Biosciences, a US-based gene therapy developer spun out of University of California (UC) Berkeley, has filed for an initial public offering.
Founded in 2011, Caribou is using Crispr genome editing technology to develop modified cell therapies for the treatment of haematologic cancers and solid tumours.
It plans to use the IPO proceeds to fund the development of its chimeric antigen receptors (CAR) T-cell and natural killer (NK) cell therapies.
The spinout was co-founded by Jennifer Doudna, a professor of biochemistry, biophysics and structural biology at UC Berkeley, and Martin Jinek, then her postdoctoral associate who has since become an assistant professor at University of Zurich.
It closed a $115m series C round the following month co-led by Farallon Capital Management, PFM Health Sciences and Ridgeback Capital Investments.
AbbVie Ventures, the corporate venturing arm of pharmaceutical firm AbbVie, also took part in the…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
